BRIACELL THERAP BCTX
4.32
0.04
0.93%
as of 25 Sep
- Market cap
- $37.2M
- P/E
- 1.9×
Follow BCTX
| Older periods | Jul '25 | Oct '25 | Jan '26 | Apr '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
5.01 | 3.42 | 10.10 | 7.07 |
Net Debt/EBITDA |
2.10 | 1.23 | 3.98 | 3.01 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.01 | 0.94 | 1.10 | 0.98 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (3.85) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(19.22) | (4.09) | (2.84) | (0.99) | |
Cash per Share |
42.23 | 5.40 | 10.67 | 3.15 | |
Shareholders Equity per Share |
40.97 | 4.96 | 10.78 | 3.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
40.97 | 4.96 | 10.78 | 3.23 | |
Free Cash Flow |
(8.13) | (7.70) | (7.97) | (7.15) | |
Working Capital |
15.95 | 8.03 | 28.99 | 21.80 | |
Capital Expenditures |
— | — | — | (0.13) | |
Net Current Asset Value |
15.61 | 7.62 | 28.80 | 21.73 | |
| Other line items | |||||
Quick Ratio |
5.01 | 3.42 | 10.10 | 7.07 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(19.22) | (4.09) | (2.84) | (0.97) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Average Receivables |
2.43 | 1.80 | 2.21 | 2.46 | |
Average Payables |
5.23 | 3.18 | 3.44 | 2.73 | |
Average Assets |
13.76 | 11.74 | 21.48 | 22.04 | |
Average Common Equity |
7.32 | 6.53 | 16.72 | 17.68 | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates